El interés en corto de Lion Group Holding da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Lion Group Holding. Los datos de interés en corto se actualizan cada dos semanas.

Lion Group Holding (NASDAQ:LGHL) Bolsa, Informe de interés en corto

Lion Group Holding

Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.

Lion Group Holding Ltd. - American Depositary Share

Lion Group Holding Ltd

WIIM

FIVE

Five Below shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 guidance above estimates.

The round of 64 NCAA Men's National Basketball Tournament games kick off Thursday with teams competing for a championship and fans competing for the near-impossible task of<a href="https://www.benzinga.com/general/education/25/03/44404112/march-madness-perfect-brackets-near-impossible-odds-among-the-big-payouts-is-the-x-offer-for-trip-to-mars"> creating a perfect bracket.</a>
Here's a look at the betting odds and favorites and the one stat that has correctly predicted winners since 2002.
How to Watch March Madness Games: Like past years, the 2025 March Madness games will be split for the first several rounds between media rights partners Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) and Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>).
The first two days of the round of 64 games take place on March 20 and March 21 followed by games to decide the Sweet 16 on March 22 and March 23.
The games will air on CBS, truTV, TBS and TNT.
The Final Four semifinals will take place on April 5, with CBS having the rights to this year's games. The championship game will air on April 7, also on CBS.
Read Also: <a href="https://www.benzinga.com/general/sports/25/03/44359867/robinhood-launches-march-madness-event-contracts-with-kalshi-change-the-world-of-finance-and-trading">Robinhood Launches March Madness Event Contracts With Kalshi: &#8216;Change The World Of Finance And Trading&#8217;</a>
Betting Odds: Here are the current betting odds for the favorites in the 2025 NCAA Men's National Basketball Tournament and their seeds, with odds from DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>):
<ul>
<li>Duke (1): +320</li>
<li>Florida (1): +380</li>
<li>Auburn (1): +400</li>
<li>Houston (1): +600</li>
<li>Tenneessee (2): +2,200</li>
<li>Alabama (2): +2,200</li>
<li>Michigan State: (2): +2,500</li>
<li>St. Johns (2): +2,800</li>
<li>Texas Tech (3): +3,500</li>
<li>Maryland (4): +4,500</li>
</ul>
As expected, the one-seeds are the betting favorites followed by the two-seeds. A three-seed and four-seed rank ninth and tenth in the odds respectively where odds start to change based on paths to the Final 4 and difficulty of region instead of seeding.
Betting Stat to Know: When looking for a winner from the 64 teams, many people will pick a 1-seed or a 2-seed as they have won the most tournaments.
Since expanding to the field of 64, one through three seeds have won over 85% of the time, with other winners often having some luck, an easier than expected field or fitting into strong offensive and defensive efficiency rankings.
Dating back to 1999,&nbsp;Ken Pomeroy&nbsp;has provided basketball rankings known as&nbsp;<a href="https://kenpom.com/index.php?s=RankAdjDE" target="_blank" rel="noreferrer noopener">KenPom&nbsp;</a>that take into account offensive and defensive efficiencies and also predicts which teams would win in matchups.
Since 2002, all the teams to win the National Championship have ranked as a top 25 adjusted defensive efficiency and top 40 adjusted defensive efficiency based on the KenPom rankings.
That narrows down this year's list to the following teams, with their respective seeds and betting odds:
<ul>
<li>Houston (1): +600</li>
<li>Tennessee (2): +2,200</li>
<li>Duke (1): +320</li>
<li>Michigan State (2): +2,500</li>
<li>Maryland (4): +4,500</li>
<li>Florida (1): +380</li>
<li>Iowa State (3): +4,500</li>
<li>Auburn (1): +400</li>
<li>Clemson (5): +8,000</li>
<li>UCLA (7): +15,000</li>
<li>Louisville (8): +10,000</li>
<li>Mississippi (6): +16,000</li>
</ul>
Since 2002, all but two teams that won the championship ranked as a top 20 adjusted offensive efficiency and top 20 adjusted defensive efficiency team based on the KenPom rankings.
This would keep only the following teams in the running:
<ul>
<li>Houston: 2nd defensive, 10th offensive</li>
<li>Tennessee: 3rd defensive, 18th offensive</li>
<li>Duke: 4th defensive, 3rd offensive</li>
<li>Florida: 9th defensive, 1st offensive</li>
<li>Auburn: 12th defensive, 2nd offensive</li>
</ul>
Who the Public is Betting On: According to <a href="https://x.com/DKSportsbook/status/1902049909962109280">DraftKings</a>, these are the most popular championship bets with the odds at the time of the tweet and the percent of betting handle.
<ul>
<li>Duke: +350, 20% of handle</li>
<li>Florida: +400, 10% of handle</li>
<li>Auburn: +350, 9% of handle</li>
<li>UConn: +7,500, 7% of handle</li>
<li>Alabama: +1,800, 6% of handle</li>
<li>Houston: +600, 6% of handle</li>
<li>Kansas: +7,500, 5% of handle</li>
<li>Kentucky: +5,500, 5% of handle</li>
<li>St. John's: +2,800, 4% of handle</li>
<li>Michigan State: +2,500, 4% of handle</li>
</ul>
The most bet on teams are three of the one-seeds, but then it quickly turns with Connecticut, who is an 8-seed listed fourth. The team is trying to win a third straight championship, but will face tougher odds given its seeding. Alabama ranks first among two-seeds as the fifth most bet on team.
On <a href="https://fantasy.espn.com/games/tournament-challenge-bracket-2025/?gad_source=1&amp;gclid=Cj0KCQjw1um-BhDtARIsABjU5x4aFgCvz02sAi0sVJiO2PAY8N8YfJphaWHBkMadceAqsl84XZldK00aAq0KEALw_wcB">ESPN </a>where millions fill out brackets with up to 25 allowed per person, these are the most bet on champions and the percent of bracket they&#8217;re picked in:
<ul>
<li>Duke: 25.1%</li>
<li>Florida: 21.3%</li>
<li>Auburn: 10.8%</li>
<li>Houston: 8.8%</li>
<li>St. John's: 4.9%</li>
<li>Michigan State: 4.5%</li>
</ul>
The public clearly loves Duke, Florida and Auburn as they rank as the top three for betting volume at DraftKings and on ESPN's tournament challenge page. On ESPN, these three one-seeds make up over 57% of brackets submitted.
Bracket Challenges: There are many ways to compete in bracket challenges with ESPN and other sports media outlets offering contests.
Social media platform X also has a Bracket Challenge that is offering a chance to win a trip to Mars if anyone has a perfect bracket. The cash prize is still $100,000 for first if there is no winner.
DraftKings and Pepsi <a href="https://www.draftkings.com/zerorightbracket">return </a>with the zero challenge with the goal of picking all 63 games wrong for a perfect imperfect bracket.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/04/38170865/uconn-wins-back-to-back-ncaa-basketball-title-heres-how-much-you-could-have-made-following" target="_blank" rel="noreferrer noopener">UConn Wins Back-To-Back NCAA Basketball Title: Here's How Much You Could Have Made Following Biden, Obama In March Madness Bracket</a></li>
</ul>
Photo: Benzinga

Sports Betting

Sports

DKNG

PARA

PARAA

March Madness 2025: How To Watch, Betting Odds And The One Stat That Could Determine A Winner

Earnings

News

IPSC

Century Therapeutics FY24 EPS $(1.61) Up From $(2.30) YoY; Revenue $6.59M Up From $2.24M YoY

Guidance

Five Below Sees FY25 Adj. EPS $4.10-$4.72, Revenue $4.21B-$4.33B

In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering.

Offerings

AKBA

Akebia Therapeutics Commences Public Offering; No Terms Disclosed

TWFG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWFG#NASDAQ">TWFG</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.11 by 72.73 percent. The company reported quarterly sales of $51.70 million which beat the analyst consensus estimate of $49.21 million by 5.06 percent.

Earnings Beats

TWFG

TWFG Q4 2024 Adj EPS $0.19 Beats $0.11 Estimate, Sales $51.70M Beat $49.21M Estimate

<ul>
<li>Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies</li>
<li>New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 &nbsp;</li>
<li>Cash runway estimate extended into fourth quarter of 2026 &nbsp;</li>
</ul>
PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:<a href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024.

Biotech

General

Century Therapeutics Announces Preclinical Pipeline Re-Prioritization To Focus On Four Potentially Transformative Programs To Advance Toward Clinic, Led By CNTY-308 In B-cell Mediated Autoimmune Diseases And Malignancies; New Concentrated Clinical Focus For CNTY-101 Based On Unique Profile With Transformational Potential In Autoimmune Disease; Data Anticipated In 2025

Federal Reserve Chairman Jerome Powell indicated that inflation driven by new trade tariffs might be &#8220;transitory,&#8221; evoking comparisons to the Fed's 2022 misstep when it wrongly classified inflation as a <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44403637/fed-holds-rates-while-growth-forecasts-slip-inflation-projections-rise">short-lived phenomenon.</a>
Speaking Wednesday following the Federal Open Market Committee's decision to hold rates at 4.25%-4.50%, Powell said the Fed is not in hurry to adjust interest rates and policymakers can &#8220;wait for clarity&#8221; before making moves.
<h3 class="wp-block-heading">How Much Of Inflation Is Due to Tariffs?</h3>
The Fed's updated macroeconomic projections show a slowing economy and stubbornly high inflation, raising concerns about stagflation. Growth forecasts for 2025 were revised downward, with real GDP now expected to expand 1.7%, down from December's 2.1% estimate. 
The Fed's preferred measure, the Personal Consumption Expenditures price index, is now expected to hit 2.7% in 2025, up from 2.5%. Core PCE, which strips out food and energy costs, was revised from 2.5% to 2.8% for 2025.
Powell admitted it is &#8220;very challenging&#8221; to isolate tariff-driven inflation from broader price pressures. 
&#8220;Some of it—a good part of it—is coming from tariffs,&#8221; he said. The difficulty lies in tracking which price increases are directly tied to tariffs and which are due to other economic factors.
Tariff-related inflation could be &#8220;transitory&#8221;, Powell said, depending on how quickly it moves through the economy. If inflation expectations remain anchored and the effects fade, the Fed may opt to look past these price increases.
Yet, some of its effects are already visible.
&#8220;We have had two very strong goods inflation readings in the last two months, which is very unexpected,&#8221; Powell said, suggesting that businesses may be preemptively raising prices in anticipation of tariffs. 
A similar dynamic occurred when washing machines were tariffed in 2018—prices on both washers and dryers jumped, even though only one was subject to tariffs.
The Fed is also factoring in potential retaliatory tariffs from other countries. Staff forecasts assume &#8220;full retaliation,&#8221; though the exact economic impact remains uncertain. 
Powell indicated that &#8220;when we actually know the specifics, we will be able to have a better-informed forecast.&#8221;
<h3 class="wp-block-heading">Powell Dismisses UMich Consumer Inflation Worries, Downplays Recession Fears</h3>
Recent surveys, including the University of Michigan Consumer Sentiment Index, indicate rising uncertainty among households and businesses, with inflation expectations soaring sharply as economic players anticipate tariffs. 
Powell downplayed the University of Michigan report, calling it an &#8220;outlier&#8221; compared to other measures of long-term inflation expectations.
Despite rising inflation expectations, the Fed is still projecting two rate cuts in 2025. Powell said weaker growth and higher inflation are &#8220;balancing each other out,&#8221; leading policymakers to maintain their current stance.
&#8220;We think our policy is in a good place,&#8221; Powell said. 
Powell said that while some forecasters have slightly raised the probability of a recession, the risk remains &#8220;moderate&#8221; and &#8220;not high.&#8221; He noted that while survey data from businesses and households show increased uncertainty, the hard economic data—such as GDP growth and employment—remains solid.
<h3 class="wp-block-heading">Market Reactions: Stocks Rally, Bitcoin Tops $85,000</h3>
Risk sentiment rippled through risky assets after Powell&#8217;s remarks on Wednesday.
The S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – rallied 1.4% going into the closing bell, while the tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), soared 1.8%. 
Small caps outperformed large-cap counterparts, with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) up 2%. 
Short-dated Treasury yields fell by 5 basis points to below 4% and the U.S. dollar index (DXY) trimmed session gains to 0.3%. Gold rose 0.5% to nearly $3,050 per ounce, further extending record highs. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) soared 3.3% to above $85,000, hitting a 10-session high.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44399554/analysts-see-upside-for-95-of-sp-500-stocks-how-nvidia-tesla-stack-up">Analysts See Upside For 95% Of S&amp;P 500 Stocks: How Nvidia, Tesla Stack Up</a></li>
</ul>
Photo courtesy of the Federal Reserve.

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

Tariff Inflation May Be 'Transitory,' Powell Says: Stocks Rally, Bitcoin Clears $85,000 As Bulls Return

scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is unchanged from the same period last year. The company reported quarterly sales of $12.20 million which beat the analyst consensus estimate of $12.08 million by 0.96 percent. This is a 100.13 percent increase over sales of $6.10 million the same period last year.

SCPH

scPharmaceuticals Q4 2024 GAAP EPS $(0.35) Beats $(0.38) Estimate, Sales $12.20M Beat $12.08M Estimate

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $5.408 million which beat the analyst consensus estimate of $4.827 million by 12.02 percent. This is a 14.07 percent increase over sales of $4.741 million the same period last year.

ICAD

icad Q4 2024 Adj. EPS $(0.03) Beats $(0.05) Estimate, Sales $5.408M Beat $4.827M Estimate

Five Below Sees Q1 Adj. EPS $0.50-$0.61 vs $0.49 Est., Revenue $905M-$925M vs $898.075M Est.

<h2>Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod&#xAE; 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections</h2>
Business Wire
<ul>
<li>First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic targets with injections</li>
<li>People using Omnipod 5 had significantly improved HbA1c levels (average reduction of -0.8%) compared with those using multiple daily injections with a continuous glucose monitor at the end of the three-month study period</li>
<li>Omnipod 5 was also linked to dramatic improvements in glucose with people spending an average of +5.4 hours more per day with glucose levels in the target range without an increase in hypoglycemia</li>
</ul>

PODD

Insulet's RADIANT Trial Shows Omnipod 5 Improves Glycemic Control by 0.8% Over Three Months; Achieves +5.4 Hours in Target Glucose Range Daily; Primary Endpoint Met

Trading Ideas

Century Therapeutics Shares Halted, News Pending

RYTM

Rhythm Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour And Welfare For Setmelanotide As A Treatment For Acquired Hypothalamic Obesity

Five Below Q4 2024 Adj. EPS $3.48 Beats $3.38 Estimate, Sales $1.391B Beat $1.386B Estimate

CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) reported quarterly earnings of $0.02 per share. This is a 106.06 percent increase over losses of $(0.33) per share from the same period last year. The company reported $7.41 million in sales this quarter. This is a 80.35 percent increase over sales of $4.11 million the same period last year.

CVD Equipment Q4 EPS $0.02 Up From $(0.33) YoY, Sales $7.41M Up From $4.11M YoY

9 analysts have expressed a variety of opinions on Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Quanta Services and provided 12-month price targets. The average target is $352.89, accompanied by a high estimate of $407.00 and a low estimate of $300.00. This current average represents a 2.48% decrease from the previous average price target of $361.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1742414476_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Quanta Services. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$343.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$316.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$323.00</td>
<td>$388.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$350.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$371.00</td>
<td>$394.00</td>
</tr>
<tr>
<td>Drew Chamberlain</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$323.00</td>
<td>$297.00</td>
</tr>
<tr>
<td>Sherif El-Sabbahy</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$407.00</td>
<td>-</td>
</tr>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$388.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$398.00</td>
<td>$399.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Quanta Services. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quanta Services compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Quanta Services's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Quanta Services's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PWR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Quanta Services analyst ratings.</a>
<h2>Discovering Quanta Services: A Closer Look</h2>
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric infrastructure and underground utility and infrastructure.
<h3>Quanta Services's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Quanta Services displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.3%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 4.66%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.24%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Quanta Services's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.63%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Quanta Services's debt-to-equity ratio is below the industry average. With a ratio of 0.61, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Quanta Services's Future

Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $193.71, along with a high estimate of $225.00 and a low estimate of $168.00. A 7.9% drop is evident in the current average compared to the previous average price target of $210.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1742414469_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Ferguson Enterprises among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Baumann</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$189.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$168.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$189.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Sam Reid</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Scott Schneeberger</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$189.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Sam Reid</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Annelies Vermeulen</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$204.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$211.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$193.00</td>
<td>-</td>
</tr>
<tr>
<td>Arnaud Lehmann</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$189.00</td>
<td>$221.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ferguson Enterprises. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ferguson Enterprises compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ferguson Enterprises's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Ferguson Enterprises's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FERG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ferguson Enterprises analyst ratings.</a>
<h2>Get to Know Ferguson Enterprises Better</h2>
Ferguson distributes plumbing and HVAC products to North American repair, maintenance and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 36,000 suppliers. Ferguson engages customers through approximately 1,800 North American branches, over the phone, online, and in residential showrooms. According to Modern Distribution Management, Ferguson is the largest plumbing distributor and second-largest HVAC distributor (next to Watsco) in North America. The firm sold its UK business in 2021 and is now solely focused on the North American market.
<h3>Breaking Down Ferguson Enterprises's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Ferguson Enterprises's remarkable performance in 3 months is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 2.98%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Ferguson Enterprises's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.02%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ferguson Enterprises's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.95%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ferguson Enterprises's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.65% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ferguson Enterprises's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FERG

Where Ferguson Enterprises Stands With Analysts

In the last three months, 4 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for HealthEquity, revealing an average target of $117.25, a high estimate of $125.00, and a low estimate of $112.00. Witnessing a positive shift, the current average has risen by 6.83% from the previous average price target of $109.75.
<img src="https://www.benzinga.com/files/images/story/2025/1742414451_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HealthEquity. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into HealthEquity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Get to Know HealthEquity Better</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Understanding the Numbers: HealthEquity's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.55% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.27%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: HealthEquity's debt-to-equity ratio is below the industry average at 0.53, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess HealthEquity: What You Need To Know

Walgreens Boots Alliance's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NYSE">WBA</a>) short percent of float has fallen 6.14% since its last report. The company recently reported that it has 62.97 million shares sold short, which is 8.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Walgreens Boots Alliance Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742414449_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Walgreens Boots Alliance has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Walgreens Boots Alliance's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Walgreens Boots Alliance's peer group average for short interest as a percentage of float is 1.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Walgreens Boots Alliance?

Press Releases

Lion Group Holding Announced Receipt of Nasdaq Listing Delinquency Notice

Fintech

Lion Group Holding Announced the Launch of Multi-Currency Account Services Powered by AI

Lion Announces Unaudited Full Year 2023 Financial Results

Lion Group Holding Plans to Use GPT-4o to Enhance Products and Services

Commodities

Lion Group Holding Makes Strategic Investment of Agunua Technology, to Explore New Opportunities in Carbon Finance

LGHL

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

Comments

Lion Group Holding

Interés en corto

Lion Group Holding (NASDAQ:LGHL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL